May 20, 2008 - Pro-Pharmaceuticals, Inc. (Amex: PRW), a Company developing carbohydrate-based targeted therapeutic compounds to treat cancer and fibrosis, has completed an important step toward submission of a New Drug Application (NDA) for DAVANAT(R) by filing the Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA).
"The FDA recommended that we provide the chemistry, manufacturing and control information necessary to support an NDA. The DMF submission is an important step in our commercialization strategy for DAVANAT(R)," said Eliezer Zomer, Ph.D., Executive Vice President, Product Development & Manufacturing. "We are currently in discussions with potential pharmaceutical partners to broaden the use of DAVANAT(R) with other therapies. We are also in discussions to license, market and sell DAVANAT(R) on a regional basis internationally. The DMF filing will help to expedite these collaborations."
No comments:
Post a Comment